Correlation of 3-dimensionally quantified intraretinal and subretinal fluid with visual acuity in neovascular age-related macular degeneration

JAMA Ophthalmology

Volumn 134, Issue 2, 2016, Pages 182-190

  Waldstein, Sebastian M ^a   Philip, Ana Maria ^a   Leitner, Roland ^a   Simader, Christian ^a   Langs, Georg ^a   Gerendas, Bianca S ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CORRELATIONAL STUDY; FEMALE; HUMAN; INTRARETINAL CYSTOID FLUID; MALE; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PATIENT REFERRAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RETINA EDEMA; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY; VISUAL ACUITY CHART; ANTAGONISTS AND INHIBITORS; CYST FLUID; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; THREE DIMENSIONAL IMAGING; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BIOMARKERS; CYST FLUID; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; IMAGING, THREE-DIMENSIONAL; INTRAVITREAL INJECTIONS; MALE; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84958576660     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2015.4948     Document Type: Article

References (25)

1. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
2. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
3. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science. 1991;254(5035): 1178-1181.
4. Keane PA, Patel PJ, Liakopoulos S, Heussen FM, Sadda SR, Tufail A. Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol. 2012;57(5):389-414.
5. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4): 566-583.
6. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248.
7. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
8. Busbee BG, Ho AC, Brown DM, et al; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5): 1046-1056.
9. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382 (9900):1258-1267.
10. Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol. 2008;92(3): 361-364.
11. Jaffe GJ, Martin DF, Toth CA, et al; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2013;120(9):1860-1870.
12. Simader C, Ritter M, Bolz M, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121(6): 1237-1245.
13. Ting TD, Oh M, Cox TA, Meyer CH, Toth CA. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthalmol. 2002;120(6):731-737.
14. Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122 (4):822-832.
15. Patel PJ, Chen FK, Rubin GS, Tufail A. Intersession repeatability of visual acuity scores in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(10):4347-4352.
16. Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci. 2011;52(5):2741-2748.
17. Liu M, Wang P-W, Haskova Z. Baseline predictors of early visual acuity improvement in RVO patients treated with ranibizumab in the SHORE study. Invest Ophthalmol Vis Sci. 2015;56 (7):5802.
18. Sophie R, Lu N, Campochiaro PA. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology. 2015;122(7):1395-1401.
19. Schlegl T, Waldstein SM, Vogl WD, Schmidt-Erfurth U, Langs G. Predicting semantic descriptions from medical images with convolutional neural networks. Inf Process Med Imaging. 2015;24:437-448.
20. Willoughby AS, Ying G-S, Toth CA, et al; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Subretinal hyperreflective material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2015;122(9):1846-1853, e5.
21. Hoerster R, Muether PS, Sitnilska V, Kirchhof B, Fauser S. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion. Retina. 2014;34(9):1767-1773.
22. Ristau T, Keane PA, Walsh AC, et al. Relationship between visual acuity and spectral domain optical coherence tomography retinal parameters in neovascular age-related macular degeneration. Ophthalmologica. 2014;231(1):37-44.
23. Kim YM, Kim JH, Koh HJ. Improvement of photoreceptor integrity and associated visual outcome in neovascular age-related macular degeneration. Am J Ophthalmol. 2012;154(1): 164-173, e1.
24. Montuoro A, Wu J, Waldstein S, et al. Motion artefact correction in retinal optical coherence tomography using local symmetry. Med Image Comput Comput Assist Interv. 2014;17(pt 2):130-137.
25. Wu J, Gerendas BS, Waldstein SM, Langs G, Simader C, Schmidt-Erfurth U. Stable registration of pathological 3D SD-OCT scans using retinal vessels. Paper presented at: Ophthalmic Medical Image Analysis First International Workshop; September 14, 2014; Boston, MA.